Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

Launched by CENTER EUGENE MARQUIS · Feb 4, 2019

Keywords

ClinConnect Summary

The TEMPOS-GEniToUrinary Group (GETUG) study is examining two different treatments for prostate cancer to see which one is better at preventing erectile dysfunction. The trial involves 240 men with low to intermediate risk prostate cancer who are being treated with either brachytherapy or stereotactic body radiotherapy (SBRT). Brachytherapy involves placing radioactive seeds in the prostate, while SBRT uses targeted radiation in just a few sessions. The main goal of the study is to compare these two treatments not only in terms of their effectiveness but also their costs and impact on quality of life over five years.

To be eligible for this trial, participants need to have a confirmed diagnosis of prostate cancer that fits specific criteria, such as a low PSA level and a certain type of cancer cell score. They should not be undergoing other treatments that could interfere with the study. Men taking part in this research will be monitored for outcomes like erectile function and any side effects from the treatments, helping to determine the best approach for managing prostate cancer while minimizing complications. This study is important because it will help doctors and healthcare decision-makers understand which treatment is more cost-effective and beneficial for patients in the long term.

Gender

MALE

Eligibility criteria

• • Main inclusion criteria
• • Biopsy proven prostate adenocarcinoma,
• • Low risk prostate cancer according to d'Amico (T1-T2a and PSA \<10 ng/ml, and Gleason score 6) or intermediate risk prostate cancer according d'Amico but excluding tumor with Gleason score 7 (4 + 3),
• • Indication of a curative treatment by brachytherapy validated in multidisciplinary consultation meeting,
• • Main exclusion criteria
• • Androgen deprivation therapy,
• • Contraindication for prostate Iodine 125 brachytherapy (Prostate volume \> 50 cc, impossibility if general anesthesia).
• • Contraindication for Resonance Magnetic Imagery (RMI) (claustrophobia, pacemaker)
• • Participation to another research which could have an impact on the study treatment and the outcomes